Cell signaling

StemSynergy Therapeutics’ Notch1-Selective Small Molecule Inhibitor Prevents Tumor Growth by Ablation of Cancer Stem Cells

Wednesday, April 14, 2021 - 9:05pm

StemSynergy Therapeutics, Inc., who collaborated on this study holds worldwide exclusivity to develop these molecules for the clinic.\n"The Notch pathway is an extremely attractive target for cancer therapeutics, as it is a critical driver of many human cancers.

Key Points: 
  • StemSynergy Therapeutics, Inc., who collaborated on this study holds worldwide exclusivity to develop these molecules for the clinic.\n"The Notch pathway is an extremely attractive target for cancer therapeutics, as it is a critical driver of many human cancers.
  • "Specifically, NADI-351 clears cancer stem cells by starving them of Notch signaling and causes cell death in tumors, including esophageal and triple-negative breast cancer.
  • At the same time this breakthrough science is being published, StemSynergy Therapeutics is developing this class of compound for clinical evaluation.
  • Our mission is to optimize efficacy against the pathways required to drive cancer stem cells, such as the Wnt, Sonic Hedgehog and Notch signaling pathways.

BeiGene Presents Clinical Data on Sitravatinib in Combination with Tislelizumab at the AACR Annual Meeting 2021

Sunday, April 11, 2021 - 9:00pm

At the time of data cutoff, 16 patients (64%) remained on study treatment.

Key Points: 
  • At the time of data cutoff, 16 patients (64%) remained on study treatment.
  • The combination of sitravatinib and tislelizumab was generally well tolerated and showed promising antitumor activity among patients with advanced PROC, including those who were heavily pretreated.
  • Sitravatinib targets the VEGFR and TAM (TYRO3, AXL, MERTK) receptor families, which are implicated in orchestrating an immunosuppressive tumor microenvironment (TME).
  • We currently market two internally discovered oncology medicines: BTK inhibitor BRUKINSA\xc2\xae (zanubrutinib) in the United States and China, and anti-PD-1 antibody tislelizumab in China.

ImmunoPrecise Launches TATX-112 Candidate Antibody Program, for the Treatment of Cancer and Alzheimer’s Disease

Thursday, April 8, 2021 - 1:02pm

In contrast, Talem has developed the TATX-112 antibodies with the goal of specifically blocking the interaction between the target and its ligand, e.g.

Key Points: 
  • In contrast, Talem has developed the TATX-112 antibodies with the goal of specifically blocking the interaction between the target and its ligand, e.g.
  • That higher specificity is expected to increase the therapeutic window by lowering the potential risk of side effects and positively impacting treatment efficacy.
  • Additionally, the targets expression profile makes this membrane protein a promising candidate for antibody-drug conjugate-based therapies.
  • Alzheimers and other neurodegenerative diseases are associated with reduced expression levels of the target and impaired receptor signaling.

BioTheryX Announces Expansion of Scientific Advisory Board

Wednesday, April 7, 2021 - 1:00pm

SAN DIEGO, April 7, 2021 /PRNewswire/ --BioTheryX, Inc., a clinical-stage company focused on degrading proteins to create life-saving medicines, today announced the expansion of its Scientific Advisory Board (SAB) with the appointment of three new members: David Komander, Ph.D., Kevan M. Shokat, Ph.D. and Peter Walter, Ph.D.

Key Points: 
  • SAN DIEGO, April 7, 2021 /PRNewswire/ --BioTheryX, Inc., a clinical-stage company focused on degrading proteins to create life-saving medicines, today announced the expansion of its Scientific Advisory Board (SAB) with the appointment of three new members: David Komander, Ph.D., Kevan M. Shokat, Ph.D. and Peter Walter, Ph.D.
  • His research work focuses on signaling pathways regulating innate immunity and inflammation, particularly in the context of cancer.
  • His lab deciphered key steps in the activation of the NFkB and Wnt signaling pathways and studied them in animal models of cancer.
  • This technology is designed to utilize the body's own protein disposal system to selectively degrade and remove disease-causing proteins.

VistaGen’s PH10 Nasal Spray Demonstrates Different Mechanism of Action from Benzodiazepines in Preclinical Study

Thursday, March 11, 2021 - 1:30pm

Using in vitro patch clamp electrophysiology, PH10 had no agonist or antagonist effects on GABA receptors.

Key Points: 
  • Using in vitro patch clamp electrophysiology, PH10 had no agonist or antagonist effects on GABA receptors.
  • In September 2020, the U.S. Food and Drug Administration (FDA) released a Drug Safety Communication (DSC) detailing the risks associated with use of benzodiazepines.
  • PH10 is a new generation antidepressant with a mechanism of action that is designed to be fundamentally different from all current FDA-approved antidepressants.
  • PH10 is a Phase 2 investigational pherine nasal spray designed to have rapid-onset effects and therapeutic potential in several neuropsychiatric indications involving depression.

aTyr Pharma Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting

Thursday, March 11, 2021 - 1:00pm

Details of the poster presentations are as follows:

Key Points: 
  • Details of the poster presentations are as follows:
    Neuropilin-2 (NRP2) is a cell surface receptor that plays a key role in lymphatic development and in regulating inflammatory responses.
  • In many forms of cancer, high NRP2 expression is associated with worse outcomes.
  • aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways.
  • aTyrs research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases.

Relmada Therapeutics Announces Participation in the 2021 SVB Leerink Global Healthcare Conference

Tuesday, February 23, 2021 - 1:30pm

NEW YORK, Feb. 23, 2021 /PRNewswire/ -- RelmadaTherapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS),today announced that Sergio Traversa, Chief Executive Officer of Relmada, will participate in a fireside chat at the 2021 SVB Leerink Global Healthcare Conference on Thursday, February 25, 2021 at 3:40 p.m. Eastern Time.

Key Points: 
  • NEW YORK, Feb. 23, 2021 /PRNewswire/ -- RelmadaTherapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS),today announced that Sergio Traversa, Chief Executive Officer of Relmada, will participate in a fireside chat at the 2021 SVB Leerink Global Healthcare Conference on Thursday, February 25, 2021 at 3:40 p.m. Eastern Time.
  • A live webcast of the fireside chat will be available by visiting the investors section of the Company's website at www.relmada.com .
  • Relmada' s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission.
  • Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Outlook on the Apoptosis Assay Global Market to 2028 - by Product, Technique, Assay Type, End-use and Region - ResearchAndMarkets.com

Monday, February 22, 2021 - 4:14pm

The global apoptosis assay market size is expected to reach USD 8.20 billion by 2028, according to the study.

Key Points: 
  • The global apoptosis assay market size is expected to reach USD 8.20 billion by 2028, according to the study.
  • This report gives a detailed insight into current market dynamics and provides analysis on future market growth.
  • The global apoptosis assay industry is fragmented based on product, technique, assay type, end-use, and region.
  • Based on the assay type, the apoptosis test market is classified as Caspase, DNA Fragmentation, Cell Permeability, and Mitochondrial.

Aptinyx to Participate in Upcoming Investor Conferences

Monday, February 22, 2021 - 1:30pm

Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders.

Key Points: 
  • Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders.
  • Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulaterather than block or over-activateNMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication.
  • The company has three product candidates in clinical development in central nervous system indications, including chronic pain, post-traumatic stress disorder, and cognitive impairment associated with Parkinsons disease.
  • Aptinyx is also advancing additional compounds from its proprietary discovery platform, which continues to generate a rich and diverse pipeline of small-molecule NMDA receptor modulators with the potential to treat an array of neurologic disorders.

Aptinyx to Participate at 10th Annual SVB Leerink Global Healthcare Conference

Thursday, February 11, 2021 - 1:30pm

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that company management will participate in a virtual fireside chat at the 10th Annual SVB Leerink Global Healthcare Conference on Thursday, February 25, 2021 at 10:40 a.m. EST.

Key Points: 
  • Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that company management will participate in a virtual fireside chat at the 10th Annual SVB Leerink Global Healthcare Conference on Thursday, February 25, 2021 at 10:40 a.m. EST.
  • Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders.
  • Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulaterather than block or over-activateNMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication.
  • The company has three product candidates in clinical development in central nervous system indications, including chronic pain, post-traumatic stress disorder, and cognitive impairment associated with Parkinsons disease.